Raf-kinase inhibitor GW5074 shows antibacterial activity against methicillin-resistant Staphylococcus aureus and potentiates the activity of gentamicin

Future Medicinal Chemistry

Volumn 8, Issue 16, 2016, Pages 1941-1952

  Johnston, Tatiana ^a   Hendricks, Gabriel Lambert ^a   Shen, Steven ^a   Chen, Roy Fangxing ^a   Kwon, Bumsup ^a   Kelso, Michael John ^b   Kim, Wooseong ^a   Burgwyn Fuchs, Beth ^a   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

gentamicin; GW5074; Staphylococcus aureus

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; GENTAMICIN; KANAMYCIN; STREPTOMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ENZYME INHIBITION; ERYTHROCYTE; GALLERIA MELLONELLA; HEMOLYSIS; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MAMMAL CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TRANSPOSON;

EID: 84989910128     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2016-0104     Document Type: Article

References (54)

1. Bassetti M, Righi E. Development of novel antibacterial drugs to combat multiple resistant organisms. Langenbecks Arch. Surg. 400 (2), 153-165 (2015).
2. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48 (1), 1-12 (2009).
3. Chang HH, Cohen T, Grad YH, Hanage WP, O'Brien TF, Lipsitch M. Origin and proliferation of multiple-drug resistance in bacterial pathogens. Microbiol. Mol. Biol. Rev. 79 (1), 101-116 (2015).
4. Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br. J. Pharmacol. 163 (1), 184-194 (2011).
5. Bush K. Antibiotics: synergistic MRSA combinations. Nat. Chem. Biol. 11 (11), 832-833 (2015).
6. Adnan S, Paterson DL, Lipman J, Roberts JA. Ampicillin/ sulbactam: its potential use in treating infections in critically ill patients. Int. J. Antimicrob. Agents 42 (5), 384-389 (2013).
7. Llarrull LI, Testero SA, Fisher JF, Mobashery S. The future of the beta-lactams. Curr. Opin. Microbiol. 13 (5), 551-557 (2010).
8. Leigh DA, Bradnock K, Marriner JM. Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to beta-lactamase producing bacteria. J. Antimicrob. Chemother. 7 (3), 229-236 (1981).
9. Kalan L, Wright GD. Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Rev. Mol. Med. 13, e5 (2011).
10. Liao JJ. Molecular targeting of protein kinases to optimize selectivity and resistance profiles of kinase inhibitors. Curr. Top. Med. Chem. 7 (14), 1332-1335 (2007).
11. Burk DL, Berghuis AM. Protein kinase inhibitors and antibiotic resistance. Pharmacol. Ther. 93 (2), 283-292 (2002).
12. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 43 (4), 727-737 (1999).
13. Shi K, Caldwell SJ, Fong DH, Berghuis AM. Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance. Front. Cell Infect. Microbiol. 3, 22 (2013).
14. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52 (3), 285-292 (2011).
15. Buchholtz K, Larsen CT, Hassager C, Bruun NE. Severity of gentamicin's nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin. Infect. Dis. 48 (1), 65-71 (2009).
16. Cosgrove SE, Vigliani GA, Fowler VG Jr et al. Initial lowdose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin. Infect. Dis. 48 (6), 713-721 (2009).
17. Rajamuthiah R, Fuchs BB, Jayamani E et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS ONE 9 (2), e89189 (2014).
18. Weigel LM, Clewell DB, Gill SR et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302 (5650), 1569-1571 (2003).
19. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. Genetic basis for daptomycin resistance in enterococci. Antimicrob. Agents Chemother. 55 (7), 3345-3356 (2011).
20. Ling LL, Schneider T, Peoples AJ et al. A new antibiotic kills pathogens without detectable resistance. Nature 517 (7535), 455-459 (2015).
21. Orelle C, Carlson S, Kaushal B et al. Tools for characterizing bacterial protein synthesis inhibitors. Antimicrob. Agents Chemother. 57 (12), 5994-6004 (2013).
22. BEI Resources. http://www.beiresources.org
23. Valentino MD, Foulston L, Sadaka A et al. Genes contributing to Staphylococcus aureus fitness in abscess- and infection-related ecologies. mBio 5 (5), e01729-01714 (2014).
24. Bae T, Banger AK, Wallace A et al. Staphylococcus aureus virulence genes identified by bursa aurealis mutagenesis and nematode killing. Proc. Natl Acad. Sci. USA 101 (33), 12312-12317 (2004).
25. Bae T, Glass EM, Schneewind O, Missiakas D. Generating a collection of insertion mutations in the Staphylococcus aureus genome using Bursa aurealis. Methods Mol. Biol. 416, 103-116 (2008).
26. Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J. Clin. Microbiol. 43 (1), 140-143 (2005).
27. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52 (1), 1 (2003).
28. Evans BC, Nelson CE, Yu SS et al. Ex vivo red blood cell hemolysis assay for the evaluation of pHresponsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J. Visual. Exp. (73), e50166 (2013).
29. Desbois AP, Coote PJ. Wax moth larva (Galleria mellonella): an in vivo model for assessing the efficacy of antistaphylococcal agents. J. Antimicrob. Chemother. 66 (8), 1785-1790 (2011).
30. Moy TI, Conery AL, Larkins-Ford J et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem. Biol. 4 (7), 527-533 (2009).
31. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50 (6), 2137-2145 (2006).
32. University of Nebraska Medical Center. Department of Pathology and Microbiology Center for Staphylococcal Research (CSR) Nebraska. Transposon Mutant Library. http://www.unmc.edu/pathology/csr/research/library.html
33. Tschierske M, Mori C, Rohrer S, Ehlert K, Shaw KJ, Berger- Bachi B. Identification of three additional femAB-like open reading frames in Staphylococcus aureus. FEMS Microbiol. Lett. 171 (2), 97-102 (1999).
34. Sifri CD, Begun J, Ausubel FM, Calderwood SB. Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infect. Immun. 71 (4), 2208-2217 (2003).
35. Gravato-Nobre MJ, Hodgkin J. Caenorhabditis elegans as a model for innate immunity to pathogens. Cell. Microbiol. 7 (6), 741-751 (2005).
36. Jebamercy G, Pandian SK, Balamurugan K. Changes in Caenorhabditis elegans life span and selective innate immune genes during Staphylococcus aureus infection. Folia Microbiol. (Praha) 56 (5), 373-380 (2011).
37. Rajamuthiah R, Jayamani E, Majed H et al. Antibacterial properties of 3- (phenylsulfonyl)-2-pyrazinecarbonitrile. Bioorg. Med. Chem. Lett. 25 (22), 5203-5207 (2015).
38. Kong C, Tan MW, Nathan S. Orthosiphon stamineus protects Caenorhabditis elegans against Staphylococcus aureus infection through immunomodulation. Biol. Open 3 (7), 644-655 (2014).
39. Conery AL, Larkins-Ford J, Ausubel FM, Kirienko NV. High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model. Curr. Protoc. Chem. Biol. 6 (1), 25-37 (2014).
40. Arvanitis M, Glavis-Bloom J, Mylonakis E. C. elegans for anti-infective discovery. Curr. Opin. Pharmacol. 13 (5), 769-774 (2013).
41. Tsai CJ, Loh JM, Proft T. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence 7 (3), 214-229 (2016).
42. Cameron DR, Mortin LI, Rubio A et al. Impact of daptomycin resistance on Staphylococcus aureus virulence. Virulence 6 (2), 127-131 (2015).
43. Latimer J, Forbes S, Mcbain AJ. Attenuated virulence and biofilm formation in Staphylococcus aureus following sublethal exposure to triclosan. Antimicrob. Agents Chemother. 56 (6), 3092-3100 (2012).
44. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J. Infect. Dis. 199 (4), 532-536 (2009).
45. Farha MA, Leung A, Sewell EW et al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to beta-lactams. ACS Chem. Biol. 8 (1), 226-233 (2013).
46. Browne N, Hackenberg F, Streciwilk W, Tacke M, Kavanagh K. Assessment of in vivo antimicrobial activity of the carbene silver (I) acetate derivative SBC3 using Galleria mellonella larvae. BioMetals 27 (4), 745-752 (2014).
47. Lackey K, Cory M, Davis R et al. The discovery of potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett. 10 (3), 223-226 (2000).
48. Chin PC, Liu L, Morrison BE et al. The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J. Neurochem. 90 (3), 595-608 (2004).
49. Drebes J, Kunz M, Windshugel B et al. Structure of ThiM from Vitamin B1 biosynthetic pathway of Staphylococcus aureus -insights into a novel pro-drug approach addressing MRSA infections. Sci. Rep. 6, 22871 (2016).
50. Clarke SR, Harris LG, Richards RG, Foster SJ. Analysis of Ebh, a 1.1-megadalton cell wall-associated fibronectinbinding protein of Staphylococcus aureus. Infect. Immun. 70 (12), 6680-6687 (2002).
51. Hubscher J, Jansen A, Kotte O et al. Living with an imperfect cell wall: compensation of femAB inactivation in Staphylococcus aureus. BMC Genomics 8, 307 (2007).
52. Shakya T, Stogios PJ, Waglechner N et al. A small molecule discrimination map of the antibiotic resistance kinome. Chem. Biol. 18 (12), 1591-1601 (2011).
53. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52 (3), e18-e55 (2011).
54. Tsai YT, Chuang MJ, Tang SH et al. Novel cancer therapeutics with allosteric modulation of the mitochondrial C-Raf-DAPK Complex by raf inhibitor combination therapy. Cancer Res. 75 (17), 3568-3582 (2015).